Handelsavisen
prelaunch
Companies ›Healthcare ›CNMD.K
CN
CNMD.K — NYSE Health Care Equipment & Supplies

Conmed Corp

$43,51
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
1,38 %
Op margin
7,5 %
ROE
4,5 %
Net margin
3,4 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$43,51
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Conmed Corp operates in the Health Care Equipment & Supplies industry, generating revenue through the sale of medical devices and related services.

Business. Conmed Corp (NYSE: CNMD) is a health care equipment and supplies company that operates within the medical device industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Specific details regarding its operating segments and geographic mix are not provided in the available data. The company is headquartered in the United States and is listed on the New York Stock Exchange.

Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability→
4,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CNMD.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CNMD.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Conmed Corp (CNMD.K) has entered the monitoring scope for the first time, establishing a baseline for future analysis with no prior data available for delta computation. This initial snapshot reveals a company structure characterized by a single reported officer and a shareholder base comprising 32 top holders, providing the foundational context for understanding recent ownership dynamics. The most material development involves significant activity among institutional investors, highlighted by a major modification in holdings by investor ID 587. Data detected in early July 2026 indicates a substantial shift in this investor's position as of March 31, 2026, with share counts fluctuating between 128 and 2,957 shares. This volatility in a major holder's position underscores active management of the stake during the reported period. In addition to the major holder adjustments, several notable new positions were added to the registry, all dated as of March 31, 2026, and detected in late June 2026. Investor ID 467 established a significant new holding of 16,543,000 shares, valued at approximately $16.12 million, representing a weight of roughly 0.00056%. Other new entrants include Investor ID 500 with 958,000 shares and Investor ID 486 with 209,000 shares, indicating broadened interest from multiple parties. These ownership changes matter as they reshape the shareholder landscape for Conmed Corp, introducing new capital and altering the concentration of stakes among top holders. With no analyst coverage or index membership currently recorded, these holder movements provide the primary signal of market sentiment and institutional engagement for the ticker. The combination of a major holder's position adjustment and the entry of new significant shareholders suggests a period of active repositioning within the company's investor base.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Conmed Corp (NYSE: CNMD) is a health care equipment and supplies company that operates within the medical device industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Specific details regarding its operating segments and geographic mix are not provided in the available data. The company is headquartered in the United States and is listed on the New York Stock Exchange.

    Classification85 %
    SectorHealth Care
    Industry groupHealth Care Equipment & Supplies
    AI synthesis
    GENERATED

    Conmed Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.0, indicating no reported interest-bearing debt relative to equity. The company holds total assets of $2.33 billion against total liabilities of $1.29 billion, resulting in total equity of $1.03 billion. Operating cash flow stands at $170.7 million, significantly exceeding capital expenditures of $19.8 million, suggesting strong internal cash generation capabilities. However, liquidity risk remains unassessed due to missing balance-sheet inputs for current ratio calculations, though the absence of going-concern language suggests operational stability.

    Profitability metrics indicate modest returns, with a return on equity (ROE) of 4.55% and a return on assets (ROA) of 2.02%. The company generated $1.37 billion in revenue, yielding a gross profit of $750.5 million and an operating income of $102.6 million. Net income was recorded at $47.1 million, reflecting a net margin of approximately 3.4%. Without cohort median data for direct comparison, these returns appear consistent with a mature, capital-light medical device business, though the low ROE suggests limited leverage or high equity base relative to earnings.

    The company’s operational footprint includes multiple international subsidiaries, indicating a global revenue mix. Disclosed subsidiaries include CONMED Korea Ltd, Linvatec Nederland B.V, Linvatec Polska Sp. z.o.o, Linvatec Conmed Sweden AB, Palmerton Holdings, Inc, SurgiQuest, Inc, Viking Systems, Inc, and Linvatec India Private Limited. This structure suggests exposure to both North American and European/Asian markets, though specific revenue concentration by geography or segment is not provided in the available data.

    Growth trajectory analysis is limited by the absence of historical period data. The current financial snapshot provides a single-period view of revenue and profitability, preventing year-over-year or quarter-over-quarter trend analysis. The company’s ability to sustain or grow its $1.37 billion revenue base remains unquantified in the provided inputs.

    Risk assessment highlights low dilution risk, with basic and diluted shares outstanding both at 31.15 million, indicating no significant share-based compensation expense or recent equity issuances impacting share count. The primary flagged risk is the inability to assess liquidity due to missing balance-sheet inputs, which limits the evaluation of short-term solvency. No other key flags or regulatory risks are explicitly detailed in the available data.

    Recent observations include reconciler events indicating zero analysis jobs for Conmed Corp, suggesting a lack of recent analyst coverage or data updates in the system. No significant news events, filing observations, or management signals are present in the provided data to inform recent corporate developments or strategic shifts.

    Conmed Corp (CNMD.K) has entered the monitoring scope for the first time, establishing a baseline for future analysis with no prior data available for delta computation. This initial snapshot reveals a company structure characterized by a single reported officer and a shareholder base comprising 32 top holders, providing the foundational context for understanding recent ownership dynamics. The most material development involves significant activity among institutional investors, highlighted by a major modification in holdings by investor ID 587. Data detected in early July 2026 indicates a substantial shift in this investor's position as of March 31, 2026, with share counts fluctuating between 128 and 2,957 shares. This volatility in a major holder's position underscores active management of the stake during the reported period. In addition to the major holder adjustments, several notable new positions were added to the registry, all dated as of March 31, 2026, and detected in late June 2026. Investor ID 467 established a significant new holding of 16,543,000 shares, valued at approximately $16.12 million, representing a weight of roughly 0.00056%. Other new entrants include Investor ID 500 with 958,000 shares and Investor ID 486 with 209,000 shares, indicating broadened interest from multiple parties. These ownership changes matter as they reshape the shareholder landscape for Conmed Corp, introducing new capital and altering the concentration of stakes among top holders. With no analyst coverage or index membership currently recorded, these holder movements provide the primary signal of market sentiment and institutional engagement for the ticker. The combination of a major holder's position adjustment and the entry of new significant shareholders suggests a period of active repositioning within the company's investor base.

    Key takeaways
    • Debt-free capital structure with $0 debt-to-equity ratio and strong operating cash flow of $170.7M.
    • Modest profitability with 4.55% ROE and 2.02% ROA on $1.37B revenue.
    • Global operational presence with subsidiaries in Korea, Netherlands, Poland, Sweden, India, and the US.
    • Low dilution risk with no difference between basic and diluted shares outstanding.
    • Liquidity risk unassessed due to missing current ratio data.
    • No historical growth data available to evaluate revenue trends.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $43,51
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $1.03B
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    2.0%
    ROEⓘ
    4.5%
    Cash conversionⓘ
    363.0%
    CapEx / revenueⓘ
    1.4%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships37 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries37
    EX21:02b03c73dc82EX21:02b03c73dc82Subsidiarie97%
    EX21:0a3649dde3efEX21:0a3649dde3efSubsidiarie97%
    EX21:1434578415e8EX21:1434578415e8Subsidiarie97%
    EX21:1dd5f3da79dfEX21:1dd5f3da79dfSubsidiarie97%
    EX21:21bd4cc07584EX21:21bd4cc07584Subsidiarie97%
    EX21:250c3b738b41EX21:250c3b738b41Subsidiarie97%
    EX21:28ec0514e6b0EX21:28ec0514e6b0Subsidiarie97%
    EX21:2bc09902be14EX21:2bc09902be14Subsidiarie97%
    EX21:3180d40cd0fdEX21:3180d40cd0fdSubsidiarie97%
    EX21:332e74ef3a75EX21:332e74ef3a75Subsidiarie97%
    EX21:3d6088c01598EX21:3d6088c01598Subsidiarie97%
    EX21:4ff0e5923e68EX21:4ff0e5923e68Subsidiarie97%
    EX21:57c08f0e4f96EX21:57c08f0e4f96Subsidiarie97%
    EX21:61229dec0be5EX21:61229dec0be5Subsidiarie97%
    EX21:6481b7d8f091EX21:6481b7d8f091Subsidiarie97%
    EX21:686b35228b3eEX21:686b35228b3eSubsidiarie97%
    EX21:7dad9ee6d3eaEX21:7dad9ee6d3eaSubsidiarie97%
    EX21:80c60f453e7cEX21:80c60f453e7cSubsidiarie97%
    EX21:8363f4bc81c1EX21:8363f4bc81c1Subsidiarie97%
    EX21:87fd5aac7712EX21:87fd5aac7712Subsidiarie97%
    EX21:89d4ae27f4bfEX21:89d4ae27f4bfSubsidiarie97%
    EX21:8ce21d6e39cbEX21:8ce21d6e39cbSubsidiarie97%
    EX21:929c4450d8f0EX21:929c4450d8f0Subsidiarie97%
    EX21:a4b713273a4eEX21:a4b713273a4eSubsidiarie97%
    EX21:aeeacb46f519EX21:aeeacb46f519Subsidiarie97%
    EX21:b7c74acf1f67EX21:b7c74acf1f67Subsidiarie97%
    EX21:b85899800b31EX21:b85899800b31Subsidiarie97%
    EX21:ba04d94964b3EX21:ba04d94964b3Subsidiarie97%
    EX21:ba4cff98017dEX21:ba4cff98017dSubsidiarie97%
    EX21:cc7e18e4d6c9EX21:cc7e18e4d6c9Subsidiarie97%
    EX21:cfc6806a9234EX21:cfc6806a9234Subsidiarie97%
    EX21:d2cac7d15c4dEX21:d2cac7d15c4dSubsidiarie97%
    EX21:db29c322f962EX21:db29c322f962Subsidiarie97%
    EX21:dd1954ff790dEX21:dd1954ff790dSubsidiarie97%
    EX21:e13390beb7b1EX21:e13390beb7b1Subsidiarie97%
    EX21:e51e1a10d061EX21:e51e1a10d061Subsidiarie97%
    EX21:f62cd34e5f73EX21:f62cd34e5f73Subsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate4,34
    Revenue—no estimate—no estimate1,4B USD
    Operating income—no estimate—no estimate204,6M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-31 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution7 analysts
    Strong buy0
    Buy0
    Hold6
    Sell1
    Strong sell0
    12-month price target$38,80 · Median $39,00
    Low $36,00High $40,00
    Operating income · consensus204,6M USD
    EPS surprise
    +5,7 %
    reported vs consensus · beat
    Revenue surprise
    +1,0 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$36,00
    Mean$38,80
    Median$39,00
    High$40,00
    Spot$43,51
    −10.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    Op Margin7,5 %Above median
    Net Margin3,4 %Above median
    ROE4,5 %Above median
    Capex / Rev1,4 %Above median
    D/E0,00Above median
    Cash Conv3,63Best in class

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-31 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 366 626 sh10 exercises · 26 grants19 insiders
    • Gallagher John EExecutive Vice President & CFO · RSUs (Restricted Stock Units) → Common StockAcquired 35 054grant · 2026-07-15
    • Gallagher John EExecutive Vice President & CFO · RSUs (Restricted Stock Units) → Common StockAcquired 26 875grant · 2026-07-15
    • Gallagher John EExecutive Vice President & CFO · Options To Purchase Common Stock → Common StockAcquired 30 536 @ $42,79grant · 2026-07-15
    • Martin Celine ChristineDirector · RSUs (Restricted Stock Units) → Common StockAcquired 5 603grant · 2026-07-01
    • Mirviss Jeffrey B.Director · RSUs (Restricted Stock Units) → Common StockAcquired 5 603grant · 2026-07-01
    • Farkas CharlesDirector · RSUs (Restricted Stock Units) → Common StockDisposed 668exercise · 2026-06-02
    • Kaye MarkDirector · RSUs (Restricted Stock Units) → Common StockDisposed 668exercise · 2026-06-02
    • Bronson David M.Director · RSUs (Restricted Stock Units) → Common StockDisposed 668exercise · 2026-06-02
    • Schwarzentraub Barbara JDirector · RSUs (Restricted Stock Units) → Common StockDisposed 668exercise · 2026-06-02
    • Council LaVerne HDirector · RSUs (Restricted Stock Units) → Common StockDisposed 668exercise · 2026-06-02
    • Kaye MarkDirector · RSUs (Restricted Stock Units) → Common StockAcquired 5 772grant · 2026-06-01
    • Farkas CharlesDirector · RSUs (Restricted Stock Units) → Common StockAcquired 5 772grant · 2026-06-01
    • Kelderman KimDirector · RSUs (Restricted Stock Units) → Common StockAcquired 5 772grant · 2026-06-01
    • Council LaVerne HDirector · RSUs (Restricted Stock Units) → Common StockAcquired 5 772grant · 2026-06-01
    • Bronson David M.Director · RSUs (Restricted Stock Units) → Common StockAcquired 5 772grant · 2026-06-01
    • Schwarzentraub Barbara JDirector · RSUs (Restricted Stock Units) → Common StockAcquired 5 772grant · 2026-06-01
    • Beyer PatPresident & CEO · RSUs (Restricted Stock Units) → Common StockAcquired 28 145grant · 2026-04-01
    • Lalomia BrentExecutive VP RA, QA · RSUs (Restricted Stock Units) → Common StockDisposed 75exercise · 2026-03-06
    • Pelletier Johonna MarieTreasurer and VP, Tax · RSUs (Restricted Stock Units) → Common StockAcquired 5 896grant · 2026-03-02
    • Schabacker MatthewVP GM Advanced Surgical · Options To Purchase Common Stock → Common StockAcquired 11 646 @ $45,79grant · 2026-03-02
    • Schabacker MatthewVP GM Advanced Surgical · RSUs (Restricted Stock Units) → Common StockAcquired 9 827grant · 2026-03-02
    • Ferrell John D.Executive Vice President - HR · Options To Purchase Common Stock → Common StockAcquired 10 999 @ $45,79grant · 2026-03-02
    • Ferrell John D.Executive Vice President - HR · RSUs (Restricted Stock Units) → Common StockAcquired 9 282grant · 2026-03-02
    • Moller Andrew JamesVP Corporate Controller · RSUs (Restricted Stock Units) → Common StockAcquired 5 896grant · 2026-03-02
    • Beyer PatPresident & CEO · Options To Purchase Common Stock → Common StockAcquired 68 258 @ $45,79grant · 2026-03-02

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Assets
      net_income / total_assets
    • Capex To Revenue
      capital_expenditure / revenue
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • CONMED CORPORATION Market data — financials · 2026-07-28
    • reconciler_enqueue (reconciler) on CNMD.K · 2026-07-28
    • Conmed Corp HA canonical relationships · 2026-07-28

    Ownership & reference

    Top holders

    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$49M
    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,01 %$15M
    • Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,01 %$33M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$7M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$16M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$6M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$17M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$150M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$10M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$26M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$6M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$12M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$3M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$3M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$6M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$16M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$6M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Patrick J. BeyerPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 4 sellsnet -$268K9 insiders · last 365d
    • Kaye MarkDirector · Common StockOther 668 · 2026-06-02
    • Schwarzentraub Barbara JDirector · Common StockOther 668 · 2026-06-02
    • Bronson David M.Director · Common StockOther 668 · 2026-06-02
    • Council LaVerne HDirector · Common StockOther 668 · 2026-06-02
    • Farkas CharlesDirector · Common StockOther 668 · 2026-06-02
    • Lalomia BrentExecutive VP RA, QA · Common StockOther 75 · 2026-03-06
    • Lalomia BrentExecutive VP RA, QA · Common StockOther 26 @ $39,90$1K · 2026-03-06
    • Kaye MarkDirector · Common StockOther 152 · 2026-02-24
    • Lalomia BrentExecutive VP RA, QA · Common StockOther 32 @ $40,60$1K · 2025-12-31
    • Glaze RichardChief Information Officer · Common StockSold 257 @ $41,21$11K · 2025-11-21
    • Glaze RichardChief Information Officer · Common StockOther 375 · 2025-11-20
    • Glaze RichardChief Information Officer · Common StockOther 118 @ $40,63$5K · 2025-11-20
    • Garner Todd WExecutive Vice President & CFO · Common StockSold 3 500 @ $43,00$150K · 2025-11-06
    • Foust Hollie KGeneral Counsel & Corp Sec · Common StockOther 4 000 · 2025-11-04
    • Foust Hollie KGeneral Counsel & Corp Sec · Common StockOther 1 114 @ $45,71$51K · 2025-11-04
    • Garner Todd WExecutive Vice President & CFO · Common StockOther 7 500 · 2025-10-31
    • Garner Todd WExecutive Vice President & CFO · Common StockOther 2 164 @ $44,00$95K · 2025-10-31
    • Farkas CharlesDirector · Common StockSold 897 @ $53,51$48K · 2025-09-12
    • Farkas CharlesDirector · Common StockSold 1 103 @ $53,53$59K · 2025-09-12

    Short positioning

    2.3Mshares short-8.0% vs prior
    2.47days to cover
    61.8%short of daily vol
    37fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CNMD.KCanonical
    NYSE · USD

    Intel & risk

    PredictorM&A prob3 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown
    Relationship graph
    CNMDEX21:02bEX21:0a3EX21:143EX21:1ddEX21:21bEX21:250EX21:28eEX21:2bcEX21:318EX21:332Health Care Eq
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Shareholders' equity (annual): USD 1.03BUnknown
    • Capex (annual): USD 19.81MUnknown
    • Gross profit (annual): USD 750.48MUnknown
    • Total assets (annual): USD 2.33BUnknown
    • Current assets (annual): USD 672.86MUnknown
    • Revenue (annual): USD 1.37BUnknown
    • Operating cash flow (annual): USD 170.69MUnknown
    • Total operating expenses (annual): USD 647.85MUnknown
    • EPS (basic) (annual): USD-PER-SHARES 2Unknown
    • Operating income (annual): USD 102.62MUnknown
    • Pre-tax income (annual): USD 71.12MUnknown
    • Cost of revenue (annual): USD 624.25MUnknown
    • Net income (annual): USD 47.1MUnknown
    • Interest expense (annual): USD 31.09MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES 2Unknown
    • Current liabilities (annual): USD 315.04MUnknown
    • R&D expense (annual): USD 55.88MUnknown
    • Total liabilities (annual): USD 1.29BUnknown
    • Cost of revenue (annual): USD 573.98MUnknown
    • EPS (basic) (annual): USD-PER-SHARES 4Unknown
    • EPS (diluted) (annual): USD-PER-SHARES 4Unknown
    • Gross profit (annual): USD 733.03MUnknown
    • Operating cash flow (annual): USD 166.97MUnknown
    • Shareholders' equity (annual): USD 962.68MUnknown
    Showing 24 of 36 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-30 04:36 UTCFILINGMaterial 8-K
    2026-07-29 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-15INSIDERGallagher John E acquired 35.1k sh RSUs (Restricted Stock Units) — Executive Vice President & CFO
    2026-07-15INSIDERGallagher John E acquired 26.9k sh RSUs (Restricted Stock Units) — Executive Vice President & CFO
    2026-07-15INSIDERGallagher John E acquired 30.5k sh Options To Purchase Common Stock — Executive Vice President & CFO
    2026-07-01INSIDERMirviss Jeffrey B. acquired 5.6k sh RSUs (Restricted Stock Units) — Director
    2026-07-01INSIDERMartin Celine Christine acquired 5.6k sh RSUs (Restricted Stock Units) — Director
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER6 institutional position changes flagged
    2026-06-26 03:13 UTCHOLDERInstitutional holding changed
    2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-25 03:10 UTCHOLDERInstitutional holding changed
    2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-17FILINGCURRENT REPORT →
    2026-06-04FILING8-K filing →
    2026-06-02 00:00 UTCINSIDER16 insider transactions — 2026-06 11 derivative
    2026-06-02 00:00 UTCINSIDER16 insider transactions — 2026-06 11 derivative
    2026-06-02INSIDERKaye Mark transacted 668 sh — Director
    2026-06-02INSIDERSchwarzentraub Barbara J transacted 668 sh — Director
    2026-06-02INSIDERBronson David M. transacted 668 sh — Director
    2026-06-02INSIDERCouncil LaVerne H transacted 668 sh — Director
    2026-06-02INSIDERFarkas Charles transacted 668 sh — Director
    2026-06-02INSIDERCouncil LaVerne H disposed of 668 sh RSUs (Restricted Stock Units) — Director
    2026-06-02INSIDERKaye Mark disposed of 668 sh RSUs (Restricted Stock Units) — Director
    2026-06-02INSIDERFarkas Charles disposed of 668 sh RSUs (Restricted Stock Units) — Director
    2026-06-02INSIDERSchwarzentraub Barbara J disposed of 668 sh RSUs (Restricted Stock Units) — Director
    2026-06-02INSIDERBronson David M. disposed of 668 sh RSUs (Restricted Stock Units) — Director
    2026-06-01FILINGCURRENT REPORT →
    2026-06-01INSIDERCouncil LaVerne H acquired 5.8k sh RSUs (Restricted Stock Units) — Director
    2026-06-01INSIDERKelderman Kim acquired 5.8k sh RSUs (Restricted Stock Units) — Director
    2026-06-01INSIDERFarkas Charles acquired 5.8k sh RSUs (Restricted Stock Units) — Director
    2026-06-01INSIDERKaye Mark acquired 5.8k sh RSUs (Restricted Stock Units) — Director
    2026-06-01INSIDERSchwarzentraub Barbara J acquired 5.8k sh RSUs (Restricted Stock Units) — Director
    Showing the 40 most recent of 75 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage